Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: Zhejiang Provincial People's Hospital
A phase Ⅱ open label multi-cencter clinical trail to evaluate the efficacy and safety of pembrolizumab combined with low-dose PF (cisplatin + 5-fluorouracil) in the neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma
This description comes directly from the study's public registry record.
Jiajie Xu, PhD · +86 13600517252 · 03kqyxxjj@163.com
Always discuss trial participation with your own doctor first.
| The Affiliated Hospital of Qingdao University | Qingdao, Shandong, China | Not Yet Recruiting |
| Zhejiang Provincial People's Hospital | Hangzhou, Zhejiang, China | Recruiting |
| Sir Run Run Shaw Hospital School of Medicine,Zhejiang University | Hangzhou, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, China | Recruiting |
| Ningbo Medical Center Lihuili Hospital | Ningbo, China | Recruiting |
| Tianjin Cancer Hospital Airport Hospital | Tianjin, China | Recruiting |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05446467